the esteemed founder of IDeA World College–renowned for its excellence in fashion, interior, and graphic design–this institution stands as a testament to his creative brilliance. Show Full Article ...

the esteemed founder of IDeA World College—renowned for its excellence in fashion, interior, and graphic design—this institution stands as a testament to his creative brilliance. For ...

the esteemed founder of IDeA World College—renowned for its excellence in fashion, interior, and graphic design—this institution stands as a testament to his creative brilliance. For architectural ...

Shares of telecom service provider Vodafone Idea Ltd. are currently trading with gains of over 4% on Tuesday, February 4. Finance Secretary Tuhin Kanta Pandey told CNBC-TV18 that a decision on the ...

Suitable for product designers and architects. Uizard, encapsulating the potential of AI in streamlining the design process, is a remarkable tool. It digitizes hand-drawn ideas into usable digital ...

The Sensex ended the day at 75,366.17, plunging 824.49 points or 1.08%. (Image/Freepik) Foreign institutional investors (FIIs) continued to exit stocks on Monday with net sales of over Rs 5,000 ...

One of the "picks and shovels" ideas behind AI was that data centers ... When investors take a deep look at the valuations they've been paying to chase the same 10 stocks, there could be a reckoning.

Exposed beams are a well-known ceiling design that can make your small rooms look way bigger, and they bring a certain je ne sais quoi to any space. Of course, exactly what kind of pizzazz they bring ...

Net-net, Emkay sees protectionist moves on select sectors such as steel, some changes in gold customs duty, payout of the LPG subsidy and some progress on the PLI scheme. Among likely policy ...

Investing.com-- Activist investor Ancora Holdings is preparing to launch a proxy battle against U.S. Steel, aiming to overhaul its leadership and redirect its strategy following the collapse of ...

Beam Therapeutics BEAM is developing its lead pipeline candidate, BEAM-101, a base-editing therapy, in the phase I/II BEACON study for treating sickle cell disease (SCD), an inherited blood disorder.